Chemical Structure (Xelstrym 01)
Xelstrym Patch, Extended Release
Product Images NDC 68968-0205
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Xelstrym (NDC 68968-0205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Noven Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Xelstrym 02)
Figure2 (Xelstrym 03)
Figure3 (Xelstrym 04)
This appears to be a table of data related to a study of a medication's effects on different populations. It includes information on age ranges (65-74 and greater than or equal to 75), gender, and different levels of renal impairment. There are also measurements provided for PK (pharmacokinetics) including Cmax and AUC, as well as fold change and 90% CI. However, without additional context it is not possible to know the specific medication or implications of these findings.*
Figure4 (Xelstrym 05)
This text appears to be a list of drugs and their interaction with certain enzymes in the body. Guanfacine and Venlafaxine are interacting drugs, and other drugs such as Caffeine, Dextromethorphan, Omeprazole, and Midazolam are substrates for different enzymes (CYP1A2, CYP2D6, CYP2C19, and CYP3A). There is also information on "Fold Change" and "90% CI," but without additional context, it's not clear what those mean.*
Figure5 (Xelstrym 06)
Figure6 (Xelstrym 07)
Not available.*
Figure A (not To Scale). (Xelstrym 08)
Figure A (not To Scale). (Xelstrym 09)
The text is prompting the user to select one application site, which can be either the upper arm or the upper back.*
Figure A (not To Scale). (Xelstrym 10)
Figure A (not To Scale). (Xelstrym 11)
Figure A (not To Scale). (Xelstrym 12)
Figure A (not To Scale). (Xelstrym 13)
Figure A (not To Scale). (Xelstrym 14)
Figure A (not To Scale). (Xelstrym 15)
Figure A (not To Scale). (Xelstrym 16)
Figure A (not To Scale). (Xelstrym 17)
Figure A (not To Scale). (Xelstrym 18)
Figure A (not To Scale). (Xelstrym 19)
Figure A (not To Scale). (Xelstrym 20)
Carton Label (4.5 mg)
Before using XELSTRYM, please read the Instructions for Use to learn how to apply, remove and dispose of the patch. The text below appears not to be relevant as it contains gibberish. The XELSTRYM is a transdermal system for Dextroamphetamine with a 4.5mg dosage for transdermal use only, available in a pack of 30 transdermal systems.*
Outer Carton Label (9.0 mg)
Before using XELSTRYM, refer to the Instructions for Use for guidance on how to apply, remove, and dispose of the patch. For additional details about the medication, consult the enclosed Medication Guide and Prescribing Information. The rest of the text is not available.*
Outer Carton Label (13.5 mg)
Xelstrym™ is a transdermal system containing 13.5 mg/9 hours of dextroamphetamine used for transdermal use only. The instruction manual must be read first before utilizing Xelstrym to learn how to apply, remove, and dispose of patches. The remaining text is not readable.*
Outer Carton Label (18.0 mg)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
